Biogen Idec sees revenue surge on MS drug salesMedical Marketing and MediaThe firm has seven products in Phase II clinical trials, including treatments for Hemophilia A and B, Amyotrophic Lateral Sclerosis, Chroic Lymphocitic Leukemia and Non-Hodgkin&#…
BloombergBiogen Idec Management Discusses Q2 2012 Results – Earnings Call TranscriptSeeking AlphaMoving on to daclizumab. We completed enrollment in this side, the second registrational trial for daclizumab and relapsing-remitting MS with more than 180…
Biogen Idec-Aktie: Gewinn im zweiten Quartal legt zuboerse.de (Pressemitteilung)21.09.10, Biogen Idec mögliche Konkurrenz für Multiple Sklerose-Franchise. 16.09.10, Biogen Idec "equal weight". 29.10.10, Biogen Idec Downgrade. 24.05.10, Biog…
Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second QuarterPharmaLive (press release) (subscription)… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase 3…
CORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 …MarketWatch (press release)… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase 3 A-LONG and B-L…
Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second QuarterMarketWatch (press release)… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase 3 A-LONG and B-…
Dr. Dan Peterson – Working to Turn the Tide for ME/CFSProHealthRituximab's soon to be generic status means Roche has no incentive to undertake expensive studies on its effects in CFS, and without those studies there's little hope insurance comp…
SEP : un risque de rechute majoré après arrêt du natalizumabMedscape France[Medscape France > Actualités ; 4 mai 2012]; Surveillance cardiovasculaire renforcée pour un traitement de la SEP [Medscape France > Actualités ; 2 mai 2012]; Le dac…
Immune Drug Helps With Kidney DisorderRedOrbitBecause the drug rituximab specifically targets immune cells involved in the development and progression of IMN, Piero Ruggenenti, M.D., Giuseppe Remuzzi, M.D., FRCP (from Mario Negri Institute for Pharmaco…
PharmaStarNefropatia membranosa, conferme italiane per rituximabPharmaStarRituximab, un farmaco fino ad oggi utilizzato per la terapia di malattie collegate al sistema immunitario come i linfomi e l'artrite è efficace in una malattia renale di ori…